ATR and B-cell chronic lymphocytic leukemia: Altogether, our results suggest that these CRISPR/Cas9‐edited CLL cell lines could be useful models to further predict treatment response of high risk del(11q) TP53MUT CLL cells, providing a pre‐clinical tool to explore novel therapeutic strategies such as ATR inhibitors in this subset of CLL cases.